NEW YORK (GenomeWeb) – Life science reagents company Abcam said today that it has entered an agreement to acquire antibody firm AxioMx.

The company will purchase AxioMx for $20 million upfront followed by additional performance-based payments totaling up to $25 million, which will be made over five years and will be based upon successful completion of commercial and technical milestones.

Abcam said that it plans to use AxioMx's technology to develop highly validated recombinant antibodies to add to its existing catalogue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.